Triazoles as farnesyl transferase inhibitors
    3.
    发明授权
    Triazoles as farnesyl transferase inhibitors 有权
    三唑作为法呢基转移酶抑制剂

    公开(公告)号:US07592356B2

    公开(公告)日:2009-09-22

    申请号:US11926858

    申请日:2007-10-29

    IPC分类号: A61K31/47 C07D249/08

    摘要: a prodrug, N-oxide, addition salt, quaternary amine or stereochemically isomeric form thereof, wherein L1 and L2 are R1—Y— wherein each (R1—Y)— substituent is defined independently of the other; Y is C1-4alkanediyl, C2-4alkenediyl, C2-4alkynediyl, C(═O), or a direct bond; R1 is hydrogen, cyano, aryl or a substituted or unsubstituted C1-14heterocycle; ═Z1—Z2═Z3— represents a radical of formula ═N—N═CH— (a-1), ═N—CH═N— (a-2), ═CH—N═N— (a-3); X is SO2, (CH2), wherein n is 1 to 4, C(═O), C(═S), or a direct bond; R2 is aryl, C3-7cycloalkyl, C3-7cycloalkyl substituted with one or more substituents independently selected from hydroxy, aryl, aryloxy, a substituted or unsubstituted C1-14heterocycle, C3-7cycloalkyl, hydroxycarbonyl, C1-6alkyloxycarbonyl, hydroxyC1-6alkyl, hydroxyC1-6alkyloxy, hydroxyC1-6alkylthio and arylC1-6alkylthio, C1-12alkyl or C1-12alkyl substituted with one or more substituents independently selected from hydroxy, aryl, aryloxy, a substituted or unsubstituted C1-14heterocycle, C3-7cycloalkyl, hydroxycarbonyl, C1-6alkyloxycarbonyl, hydroxyC1-6alkyl, hydroxyC1-6alkyloxy, hydroxyC1-6alkylthio and arylC1-6alkylthio; R3 is aryl, —NR5R6, a substituted or unsubstituted C1-14heterocycle, or C2-4alkenediyl substituted with a substituted or unsubstituted C1-14heterocycle or aryl; R4 is hydrogen, aryl, C3-7cycloalkyl, C1-6alkyl or C1-6alkyl substituted with C3-7cycloalkyl, hydroxycarbonyl, C1-4alkyloxycarbonyl or aryl; R5 and R6 are each independently selected from hydrogen, a substituted or unsubstituted C1-14heterocycle, aryl, C1-12alkyl and C1-12alkyl substituted with one or more substituents selected from hydroxy, aryl, aryloxy or a substituted or unsubstituted C1-14heterocycle.

    摘要翻译: 前药,N-氧化物,加成盐,季胺或其立体化学异构形式,其中L 1和L 2是R 1 -Y-,其中每个(R 1 -Y) - 取代基独立地彼此定义; Y是C1-4烷二基,C2-4亚烯基,C2-4炔二基,C(-O)或直接键; R1是氢,氰基,芳基或取代或未取代的C1-14杂环; -Z1-Z2-Z3-表示式-N-N-CH-(a-1),-N-CH-N-(a-2),-CH-N-N-(a-3) X是SO 2,(CH 2),其中n是1至4,C(-O),C(-S)或直接键; R 2是芳基,C 3-7环烷基,被一个或多个独立地选自羟基,芳基,芳氧基,取代或未取代的C 1-14杂环,C 3-7环烷基,羟基羰基,C 1-6烷氧基羰基,羟基C 1-6烷基,羟基C 1-6烷基, 被一个或多个独立地选自羟基,芳基,芳氧基,取代或未取代的C 1-14杂环,C 3-7环烷基,羟基羰基,C 1-6烷氧基羰基,C 1-6烷氧基羰基,C 1-6烷硫基, 羟基C 1-6烷基,羟基C 1-6烷氧基,羟基C 1-6烷硫基和芳基C 1-6烷硫基; R3是芳基,-NR5R6,取代或未取代的C1-14杂环,或被取代或未取代的C1-14杂环或芳基取代的C2-4亚烯基; R4是氢,芳基,C3-7环烷基,C1-6烷基或被C3-7环烷基取代的C1-6烷基,羟基羰基,C1-4烷氧基羰基或芳基; R 5和R 6各自独立地选自氢,取代或未取代的C 1-14杂环,芳基,C 1-12烷基和被一个或多个选自羟基,芳基,芳氧基或取代或未取代的C 1-14杂环的取代基取代的C 1-12烷基。

    Triazoles as farnesyl transferase inhibitors
    7.
    发明授权
    Triazoles as farnesyl transferase inhibitors 有权
    三唑作为法呢基转移酶抑制剂

    公开(公告)号:US07511061B2

    公开(公告)日:2009-03-31

    申请号:US11143814

    申请日:2005-06-02

    摘要: A prodrug, N-oxide, addition salt, quaternary amine or stereochemically isomeric form thereof, wherein L1 and L2 are R1—Y— wherein each (R1—Y)— substituent is defined independently of the other; Y is C1-4alkanediyl, C2-4alkenediyl, C2-4alkynediyl, C(═O), or a direct bond; R1 is hydrogen, cyano, aryl or a substituted or unsubstituted C1-14heterocycle; =Z1-Z2=Z3- represents a radical of formula ═N—N═CH— (a-1), ═N—CH═N— (a-2), ═CH—N═N— (a-3); X is SO2, (CH2)n wherein n is 1 to 4, C(═O), C(═S), or a direct bond; R2 is aryl, C3-7cycloalkyl, C3-7cycloalkyl substituted with one or more substituents independently selected from hydroxy, aryl, aryloxy, a substituted or unsubstituted C1-14heterocycle, C3-7cycloalkyl, hydroxycarbonyl, C1-6alkyloxycarbonyl, hydroxyC1-6alkyl, hydroxyC1-6alkyloxy, hydroxyC1-6alkylthio and arylC1-6alkylthio, C1-12alkyl or C1-12alkyl substituted with one or more substituents independently selected from hydroxy, aryl, aryloxy, a substituted or unsubstituted C1-14heterocycle, C3-7cycloalkyl, hydroxycarbonyl, C1-6alkyloxycarbonyl, hydroxyC1-6alkyl, hydroxyC1-6alkyloxy, hydroxyC1-6alkylthio and arylC1-6alkylthio; R3 is aryl, —NR5R6, a substituted or unsubstituted C1-14heterocycle, or C2-4alkenediyl substituted with a substituted or unsubstituted C1-14heterocycle or aryl; R4 is hydrogen, aryl, C3-7cycloalkyl, C1-6alkyl or C1-6alkyl substituted with C3-7cycloalkyl, hydroxycarbonyl, C1-4alkyloxycarbonyl or aryl; R5 and R6 are each independently selected from hydrogen, a substituted or unsubstituted C1-14heterocycle, aryl, C1-12alkyl and C1-12alkyl substituted with one or more substituents selected from hydroxy, aryl, aryloxy or a substituted or unsubstituted C1-14heterocycle.

    摘要翻译: 前药,N-氧化物,加成盐,季胺或其立体化学异构形式,其中L 1和L 2是R 1 -Y-,其中每个(R 1 -Y) - 取代基独立地彼此定义; Y是C1-4烷二基,C2-4亚烯基,C2-4炔二基,C(-O)或直接键; R1是氢,氰基,芳基或取代或未取代的C1-14杂环; = Z1-Z2 = Z3-表示式-N-N-CH-(a-1),-N-CH-N-(a-2),-CH-N-N-(a-3) X是SO 2,(CH 2)n,其中n是1至4,C(-O),C(-S)或直接键; R 2是芳基,C 3-7环烷基,被一个或多个独立地选自羟基,芳基,芳氧基,取代或未取代的C 1-14杂环,C 3-7环烷基,羟基羰基,C 1-6烷氧基羰基,羟基C 1-6烷基,羟基C 1-6烷基, 被一个或多个独立地选自羟基,芳基,芳氧基,取代或未取代的C 1-14杂环,C 3-7环烷基,羟基羰基,C 1-6烷氧基羰基,C 1-6烷氧基羰基,C 1-6烷硫基, 羟基C 1-6烷基,羟基C 1-6烷氧基,羟基C 1-6烷硫基和芳基C 1-6烷硫基; R3是芳基,-NR5R6,取代或未取代的C1-14杂环,或被取代或未取代的C1-14杂环或芳基取代的C2-4亚烯基; R4是氢,芳基,C3-7环烷基,C1-6烷基或被C3-7环烷基取代的C1-6烷基,羟基羰基,C1-4烷氧基羰基或芳基; R 5和R 6各自独立地选自氢,取代或未取代的C 1-14杂环,芳基,C 1-12烷基和被一个或多个选自羟基,芳基,芳氧基或取代或未取代的C 1-14杂环的取代基取代的C 1-12烷基。

    Triazoles as farnesyl transferase inhibitors

    公开(公告)号:US07049324B1

    公开(公告)日:2006-05-23

    申请号:US10130322

    申请日:2000-11-15

    摘要: a prodrug, N-oxide, addition salt, quaternary amine or stereochemically isomeric form thereof, wherein L1 and L2 are R1—Y— wherein each (R1—Y)— substituent is defined independently of the other; Y is C1-4alkanediyl, C2-4alkenediyl, C2-4alkynediyl, C(═O), or a direct bond; R1 is hydrogen, cyano, aryl or a substituted or unsubstituted C1-14heterocycle; ═Z1—Z2═Z3— represents a radical of formula ═N—N═CH— (a-1), ═N—CH═N— (a-2), ═CH—N═N— (a-3); X is SO2, (CH2)n wherein n is 1 to 4, C(═O), C(═S), or a direct bond, R2 is aryl, C3-7cycloalkyl, C3-7cycloalkyl substituted with one or more substituents independently selected from hydroxy, aryl, aryloxy, a substituted or unsubstituted C1-14heterocycle, C3-7cycloalkyl, hydroxycarbonyl, C1-6alkyloxycarbonyl, hydroxyC1-6alkyl, hydroxyC1-6alkyloxy, hydroxyC1-6alkylthio and arylC1-6alkylthio, C1-12alkyl or C1-12alkyl substituted with one or more substituents independently selected from hydroxy, aryl, aryloxy, a substituted or unsubstituted C1-14heterocycle, C3-7cycloalkyl, hydroxycarbonyl, C1-6alkyloxycarbonyl, hydroxyC1-6alkyl, hydroxyC1-6alkyloxy, hydroxyC1-6alkylthio and arylC1-6alkylthio; R3 is aryl, —NR5R6, a substituted or unsubstituted C1-14heterocycle, or C2-4alkenediyl substituted with a substituted or unsubstituted C1-14heterocycle or aryl; R4 is hydrogen, aryl, C3-7cycloalkyl, C1-6alkyl or C1-6alkyl substituted with C3-7cycloalkyl, hydroxycarbonyl, C1-4alkyloxycarbonyl or aryl; R5 and R6 are each independently selected from hydrogen, a substituted or unsubstituted C1-14heterocycle, aryl, C1-12alkyl and C1-12alkyl substituted with one or more substituents selected from hydroxy, aryl, aryloxy or a substituted or unsubstituted C1-14heterocycle.